← back to search

Johannes V. van Thienen

Dutch Cancer Society · NL
Area of research
Oncology · Molecular Biology
Research interest
Research interests include Melanoma and MAPK Pathways, Cancer Immunotherapy and Biomarkers, Cutaneous Melanoma Detection and Management, and CAR-T cell therapy research.
h-index
29
citations
5,588
works
124
NIH funding
primary concept
Medicine
email

Recent publications

A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in <i>BRAF</i> <i>V600</i> -Mutated Melanoma
Clinical Cancer Research 2024cited by 12position: middledoi
Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials
Annals of Oncology 2023cited by 119position: middledoi
Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma
New England Journal of Medicine 2022cited by 516position: middledoi
Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma
Journal of Clinical Oncology 2022cited by 269position: middledoi
Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma
Annals of Oncology 2021cited by 59position: middledoi
Cytoreductive nephrectomy and exposure to sunitinib – a <i>post hoc</i> analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial
British Journal of Urology 2021cited by 23position: middledoi
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
The Lancet Oncology 2019cited by 516position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

John B.A.G. Haanen · Nikki-Universal (Japan)3 papers (2021–2024)Christian U. Blank · Dutch Cancer Society2 papers (2023–2024)Richard A. Scolyer · Westmead Institute for Medical Research1 papers (2023–2023)Hanna Eriksson · Karolinska University Hospital1 papers (2023–2023)Cor Lieftink · Rockefeller University1 papers (2024–2024)Bastiaan Nuijen · The Netherlands Cancer Institute1 papers (2024–2024) · 1 papers (2021–2021)Liqin Wang · Nanjing Medical University1 papers (2024–2024)Maria Gonzalez · The University of Sydney1 papers (2023–2023) · 1 papers (2024–2024)Christian U. Blank · Novartis (Switzerland)1 papers (2021–2021)A. Torres Acosta · Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital1 papers (2023–2023)Sydney Ch'ng · The University of Sydney1 papers (2023–2023)Jan H.M. Schellens · University of Applied Sciences Utrecht1 papers (2024–2024)Ton N. Schumacher · Oncode Institute1 papers (2023–2023)Henk Mallo · The Netherlands Cancer Institute1 papers (2023–2023) · 1 papers (2024–2024)Lindsay G. Grijpink-Ongering · The Netherlands Cancer Institute1 papers (2023–2023)Bart A. van de Wiel · Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital1 papers (2023–2023)Rodrigo Leite de Oliveira · KU Leuven1 papers (2024–2024)